SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001479290-19-000108
Filing Date
2019-11-04
Accepted
2019-11-04 16:11:26
Documents
16
Period of Report
2019-11-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rvncq319er8-k.htm   iXBRL 8-K 49434
2 EXHIBIT 99.1 rvncq319exhibit991.htm EX-99.1 159463
8 rvnclogooct2019.jpg GRAPHIC 14927
  Complete submission text file 0001479290-19-000108.txt   386424

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20191104.xsd EX-101.SCH 4604
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rvnc-20191104_cal.xml EX-101.CAL 642
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rvnc-20191104_def.xml EX-101.DEF 1492
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20191104_lab.xml EX-101.LAB 26142
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20191104_pre.xml EX-101.PRE 13598
15 EXTRACTED XBRL INSTANCE DOCUMENT rvncq319er8-k_htm.xml XML 4473
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 191189907
SIC: 2834 Pharmaceutical Preparations